Magnesium Administration as a Treatment for Perioperative Atrial Fibrillation following Cardiac Surgery: Safety and Efficacy
- 1Department of Cardiac Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
- 2Department of Cardiac Surgery, JA Aichi Koseiren Toyota Kosei Hospital, Toyota, Aichi, Japan
Abstract
Purpose: Atrial fibrillation (AF) is a common complication after cardiac surgery, impacting recovery and outcomes. Magnesium has electrophysiological and rate-controlling effects in AF. This study evaluated the safety and the temporal association between therapeutic intravenous magnesium administration and rhythm outcomes in patients with postoperative atrial fibrillation (POAF) after cardiac surgery.
Methods: Between January 2009 and December 2016, 714 patients undergoing cardiac surgery were evaluated. After excluding 49 patients with a history of AF, 130 developed new-onset POAF. Of these, 111 patients (85.4%) received intravenous magnesium according to our institutional protocol, whereas 19 patients (14.6%) did not. Magnesium (20 mEq per dose, 1–3 doses) was administered with other antiarrhythmic agents in 40 patients (36.0%) and as monotherapy in 71 patients (64.0%). The principal efficacy analyses were restricted to the magnesium-monotherapy cohort. Serum magnesium levels after administration were monitored in 35 patients.
Results: Among the 71 patients treated with magnesium monotherapy, the heart rate significantly decreased from 114 ± 32.3 bpm to 100 ± 39.7 bpm (P <0.01), with no significant change in blood pressure. Sinus rhythm conversion occurred in 34 patients (47.9%) within 3 hours and in 60 patients (84.5%) within 24 hours. In multivariable logistic regression analysis, a higher preoperative serum magnesium concentration (adjusted OR, 1.31 per 0.1 mg/dL increase; 95% profile-likelihood CI, 1.07–1.65; P = 0.014) and later postoperative onset of POAF (adjusted OR, 1.32 per postoperative day; 95% CI, 1.07–1.68; P = 0.015) were associated with 3-hour conversion. No serious adverse events attributable to magnesium were observed in the monotherapy cohort. However, because no untreated-comparator group was available, spontaneous conversion cannot be distinguished from a treatment effect.
Conclusion: Intravenous magnesium monotherapy was associated with heart rate reduction without significant blood pressure deterioration and was followed by early sinus rhythm conversion in a substantial proportion of patients with POAF. These observational findings support the feasibility and apparent safety of this approach, but do not establish a causal antiarrhythmic effect. Prospective controlled studies are required.
Related
- Response to "Interpreting Route, Dose, and Clinical Relevance in Perioperative Magnesium Sulfate After Total Knee Arthroplasty" [Response to Letter].
- Association between early intravenous magnesium sulfate administration and mortality according to systemic immune-inflammation index in critically ill patients with acute heart failure: A retrospective cohort study.
- NLRP3 inflammasome-driven inflammation as a cause of atrial fibrillation: potential synergistic inhibition of the NLRP3 via upstream magnesium repletion and targeting NLRP3 with a downstream inhibitor
- Effect of protocolized MAGNesium replacement in critically ill patients On mortaLIty and Atrial fibrillation: protocol for the MAGNOLIA randomized controlled trial
- Exacerbation of Pre-existing Hypothyroidism Following Enarodustat Administration in a Patient on Peritoneal Dialysis: A Case Report
BibTeX
@article{terada2026magnesium,
title = {{Magnesium Administration as a Treatment for Perioperative Atrial Fibrillation following Cardiac Surgery: Safety and Efficacy}},
author = {Takafumi Terada and Yoshiyuki Tokuda and Yoshimori Araki and Akihiro Kobayashi and Osamu Kawaguchi and Eriko Koike and Masato Mutsuga},
journal = {Annals of Thoracic and Cardiovascular Surgery},
year = {2026},
month = oct,
doi = {10.5761/atcs.oa.26-00129},
url = {https://doi.org/10.5761/atcs.oa.26-00129},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Magnesium Administration as a Treatment for Perioperative Atrial Fibrillation following Cardiac Surgery: Safety and Efficacy
AU - Takafumi Terada
AU - Yoshiyuki Tokuda
AU - Yoshimori Araki
AU - Akihiro Kobayashi
AU - Osamu Kawaguchi
AU - Eriko Koike
AU - Masato Mutsuga
PY - 2026
DA - 2026/10/22
JO - Annals of Thoracic and Cardiovascular Surgery
DO - 10.5761/atcs.oa.26-00129
UR - https://doi.org/10.5761/atcs.oa.26-00129
AB - Purpose: Atrial fibrillation (AF) is a common complication after cardiac surgery, impacting recovery and outcomes. Magnesium has electrophysiological and rate-controlling effects in AF. This study evaluated the safety and the temporal association between therapeutic intravenous magnesium administration and rhythm outcomes in patients with postoperative atrial fibrillation (POAF) after cardiac surgery. Methods: Between January 2009 and December 2016, 714 patients undergoing cardiac surgery were evaluated. After excluding 49 patients with a history of AF, 130 developed new-onset POAF. Of these, 111 patients (85.4%) received intravenous magnesium according to our institutional protocol, whereas 19 patients (14.6%) did not. Magnesium (20 mEq per dose, 1–3 doses) was administered with other antiarrhythmic agents in 40 patients (36.0%) and as monotherapy in 71 patients (64.0%). The principal efficacy analyses were restricted to the magnesium-monotherapy cohort. Serum magnesium levels after administration were monitored in 35 patients. Results: Among the 71 patients treated with magnesium monotherapy, the heart rate significantly decreased from 114 ± 32.3 bpm to 100 ± 39.7 bpm (P <0.01), with no significant change in blood pressure. Sinus rhythm conversion occurred in 34 patients (47.9%) within 3 hours and in 60 patients (84.5%) within 24 hours. In multivariable logistic regression analysis, a higher preoperative serum magnesium concentration (adjusted OR, 1.31 per 0.1 mg/dL increase; 95% profile-likelihood CI, 1.07–1.65; P = 0.014) and later postoperative onset of POAF (adjusted OR, 1.32 per postoperative day; 95% CI, 1.07–1.68; P = 0.015) were associated with 3-hour conversion. No serious adverse events attributable to magnesium were observed in the monotherapy cohort. However, because no untreated-comparator group was available, spontaneous conversion cannot be distinguished from a treatment effect. Conclusion: Intravenous magnesium monotherapy was associated with heart rate reduction without significant blood pressure deterioration and was followed by early sinus rhythm conversion in a substantial proportion of patients with POAF. These observational findings support the feasibility and apparent safety of this approach, but do not establish a causal antiarrhythmic effect. Prospective controlled studies are required.
SN - 1341-1098
SN - 2186-1005
ER -